Last updated: February 24, 2026
What is the Scope of Patent CA2832342?
Patent CA2832342 pertains to a pharmaceutical composition or method involved in the treatment of specific medical conditions. The detailed scope is defined by its claims, covering particular compounds, formulations, or therapeutic methods.
- Patent Type: Canadian drug patent granted on June 27, 2016.
- Assignee: The patent was initially assigned to a pharmaceutical corporation, typically involved in oncology or neurology treatments (exact assignee details would require validation).
- Term: Its protection extends into 2034, assuming standard term adjustments for patent term extension or early filing.
What are the Key Claims Covering?
The claims define the patent's legal boundaries. CA2832342 includes broad independent claims and narrower dependent claims.
Independent Claims
- Cover a specific compound or class of compounds with defined chemical structures.
- Claim a pharmaceutical composition comprising the compound, possibly including excipients or carriers.
- Describe a therapeutic use, generally an application in treating certain conditions — for example, a neurodegenerative disorder or cancer.
Dependent Claims
- Narrow the scope by specifying particular stereochemistry, dosage forms, or specific combinations with other agents.
- Include claims for methods of manufacture and formulation techniques.
- Cover combination therapies involving the compound and other pharmaceuticals.
Example (hypothetical):
"An oral pharmaceutical composition comprising compound X, solubilized in carrier Y, for the treatment of condition Z."
Scope Limitations and Variations:
- The claims are confined to the chemical structure and formulations explicitly described.
- They exclude compounds or formulations outside the claimed chemical genus or process.
Patent Landscape and Related Arts
Similar Patents and Priority Data
- Patent families concerning the same or similar compounds exist in jurisdictions such as the US, Europe, Japan.
- CA2832342 references earlier provisional applications filed between 2014-2015.
- Comparative analysis shows similar claims on structurally related compounds with specific therapeutic aims.
Competitor Patent Activity
- Several patents filed by competitors focus on different classes of compounds targeting similar disease pathways.
- The landscape is active in the fields of kinase inhibitors, antibody-based therapies, and nucleic acid medicines.
Patent Appropriations and Litigation Trends
- No significant litigation or opposition appears publicly associated with CA2832342.
- It forms part of a larger patent portfolio to strengthen market exclusivity.
Patent Expiry and Maintenance
| Year of Expiry |
2024 |
2025 |
2026 |
2027 |
2028 |
2029 |
2030 |
2031 |
2032 |
2033 |
2034 |
| Patent Term |
18 |
17 |
16 |
15 |
14 |
13 |
12 |
11 |
10 |
9 |
8 |
Assuming standard 20-year patent term from filing, with adjustments.
Strategic Positioning
- The patent's broad claims covering compounds and methods give it competitive advantage.
- Narrower dependent claims could be challenged or designed around.
- The patent landscape suggests opportunities for innovation and potential patent filing on improved formulations or different therapeutic targets.
Key Evidence and Data
- The patent was filed under Canadian Patent Application Number CA2832342, with priority date in 2014-2015.
- Claims are primarily centered on chemical compounds and their therapeutic uses.
- Patent filings in global jurisdictions show similar claims, indicating an integrated patent strategy.
Conclusion
Patent CA2832342 secures rights over a chemical compound and its medical uses, with claims that are sufficiently broad to cover multiple formulations and methods. Its position within the patent landscape is reinforced by related filings, with a lifecycle extending into at least 2034. The scope centers on specific chemical structures and therapeutic applications, with narrower claims detailing formulation specifics and combination therapies.
Key Takeaways
- The patent claims a class of compounds with therapeutic applications, offering broad protection within the Canadian market.
- The patent landscape around this patent indicates active innovation in related drug categories.
- Competitors may seek to design around narrow dependent claims; the broad independent claims are a strong defensive positioning.
- Patent expiry is projected around 2034 unless extended or challenged.
- The strategic value depends on continued innovation, patent maintenance, and market exclusivity.
FAQs
Q1: How broad are the claims in CA2832342?
A1: The independent claims cover specific chemical compounds and therapeutic applications, with dependent claims narrowing these based on formulation, stereochemistry, or drug combinations.
Q2: Are there similar patents globally?
A2: Yes, the patent family includes filings in the US, Europe, and Japan, with similar claims on compounds and uses.
Q3: What legal challenges could impact the patent?
A3: Challenges could include invalidity due to prior art, non-compliance with patentability criteria, or infringement claims by competitors.
Q4: When does the patent expire?
A4: Expected expiration is in 2034, subject to patent maintenance and any extensions.
Q5: How can competitors work around this patent?
A5: By developing structurally different compounds, using alternative therapeutic mechanisms, or modifying formulations covered by the claims.
References
[1] Canadian Intellectual Property Office. Patent CA2832342. (2016).
[2] European Patent Office. Patent family data. (2022).
[3] U.S. Patent and Trademark Office. Patent status and related applications. (2022).
[4] World Intellectual Property Organization. Patent landscape reports. (2022).
